Develops and sells prescription medicines and vaccines, rebuilding its pipeline through acquisitions after an extraordinary pandemic revenue cycle.
Pfizer (PFE) scores 3.6 out of 10 as of , computed from its reported financial statements. That reads as low quality. The reading rests on efficiency, and growth is what holds it back.
One pillar, solvency, is unscored because the filings behind it carry too little to judge. It is shown as a dash rather than a zero, and the overall score is the weighted average of what could be scored.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
Few large companies have had their revenue base move as violently in as short a time, which punishes predictability and growth in a way that reflects real history rather than a flaw in the measurement. Solvency also carries the debt raised to fund the rebuild. A quality score here is really a question about which base you believe is the normal one.
The Quality Score for PFE stands at 3.6 out of 10 as of October 14, 2026, which puts Pfizer in the low quality band. Scores this low usually reflect thin margins, a stretched balance sheet or an erratic record, and the pillars below show which. It rolls Pfizer’s profitability, solvency, growth, efficiency and predictability into one number, each judged against the norms of its sector.
Too few Healthcare companies have a published score for a fair sector ranking yet, so Pfizer is compared with every company Lemma scores. Ranked with the 49 companies Lemma publishes, the score sits at the 6th percentile, in the bottom quarter of the group. The median across the group is 6.4, and the top quarter begins at 7.2, so Pfizer is well below the typical company here.
On profitability, Pfizer scores 4.3, an average reading. Its peers have a median of 8.1 across 34 companies, which places it well below them, at the 3rd percentile. Middling returns are common and not a flaw in themselves, though they leave less slack when costs rise or demand softens.
Solvency has no score for Pfizer. Fewer than half of the pillar’s metric weight could be computed from the reported statements, so it is drawn as a dash and left out of the overall rather than counted as a zero. For context, the median solvency score across 39 companies is 7.6. Without it the overall says nothing about how comfortably the company carries its debt.
Growth scores 0.4 out of 10, which reads as weak. Every other company in the group scores higher here, against a median of 5.3 across 47 companies. A low growth score is common for large, established companies and is not a verdict on quality on its own, but it limits how the business can compound.
On efficiency, Pfizer scores 6.3, an average reading. Its peers have a median of 6.3 across 45 companies, which places it in line with them, at the 52nd percentile. Middling efficiency is unremarkable on its own, though improvements here tend to show up in free cash flow first.
Predictability scores 3.9 out of 10, which reads as weak. The median across 49 companies is 5.6, so Pfizer is well below its peers on this pillar and ranks at the 20th percentile. A low predictability score often belongs to cyclical businesses, where good and bad years alternate with the economy or with commodity prices.
The gap between Pfizer’s best and worst pillar is wide: efficiency at 6.3 against growth at 0.4, 5.9 points apart. An average of two readings this different deserves a closer look than the headline number. Leading with efficiency points to disciplined use of capital, a strength that compounds quietly. Slow growth limits how fast the business can compound, even when everything else is in order.
Of everything that could lift Pfizer’s score, growth matters most. Bringing it up to the 5.3 median of every company scored would take the overall from 3.6 to roughly 4.8. With one pillar unscored, the overall rests on 80 of the 100 weight points, spread across the four pillars that could be measured (the full set is profitability 25, solvency 20, growth 20, efficiency 15, predictability 20).
To see what separates similar readings, compare Pfizer with the companies below, whose overall scores are nearest to its own.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Pfizer scores 3.6 out of 10, which reads as low quality. Its strongest pillar is efficiency, its weakest is growth. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Pfizer ranks at the 6th percentile of the 49 companies Lemma publishes a score for. The median there is 6.4 and the top quarter starts at 7.2, against Pfizer’s 3.6.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 14, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for PFE are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card